TSI Corp. announced that it will write down its $5 millioninvestment in its German testing and regulatory consultingsubsidiary, IBR Forschungs GmbH. TSI of Milford, Mass., willtake the one-time charge in the fourth quarter of fiscal 1993.

For various reasons, IBR was incurring significant losses andwas not expected to operate profitably without a majorfinancial commitment from TSI, which TSI (NASDAQ:TSIN) hasdecided not to make. To do that would have meant some risk toTSI, according to its chief executive officer Robert Baldridge.

TSI is a life sciences company offering in vitro and in vivopreclinical and toxicology testing services, human clinicaltesting services and diagnostic intermediate products.

(c) 1997 American Health Consultants. All rights reserved.